A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Summary

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• ALK-positive NSCLC
• ALK-Positive Lung Cancer
• ALK-positive Non-small Cell Lung Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

TRIANA Biomedicines, Inc.

Last updated on ClinicalTrials.gov

September 3, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites